In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Pfizer’s current price ($26.21) trades below a high-confidence fair value ($32.60), indicating potential undervaluation. Monte Carlo analysis shows a median of $38.02 with downside risk of 22.2%, reflecting moderate volatility and return dispersion. Financial health scores at 2.8/5 suggest fair operational stability amid valuation upside.